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Abstract: The key to reducing the individual and societal burden of age-related macular 
degeneration (AMD)-related vision loss, is to be able to initiate therapies that slow or halt 
the progression at a point that will yield the maximum benefit while minimizing personal 
risk and cost. There is a critical need to find clinical markers that, when combined with the 
specificity of genetic testing, will identify individuals at the earliest stages of AMD who 
would benefit from preventive therapies. These clinical markers are endophenotypes for 
AMD, present in those who are likely to develop AMD, as well as in those who have 
clinical evidence of AMD. Clinical characteristics associated with AMD may also be 
possible endophenotypes if they can be detected before or at the earliest stages of the 
condition, but we and others have shown that this may not always be valid. Several studies 
have suggested that dynamic changes in rhodopsin regeneration (dark adaptation kinetics 
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and/or critical flicker fusion frequencies) may be more subtle indicators of  
AMD-associated early retinal dysfunction. One can test for the relevance of these measures 
using genetic risk profiles based on known genetic risk variants. These functional measures 
may improve the sensitivity and specificity of predictive models for AMD and may also 
serve to delineate clinical subtypes of AMD that may differ with respect to prognosis  
and treatment. 
Keywords: age-related macular degeneration; endophenotype; genetic risk; preclinical 
diagnostics; retinal function; predictive modeling 
 
1. Introduction 
In the past ten years, there has been an explosion in our understanding of the genetics of age-related 
macular degeneration resulting from the initial association of age-related macular degeneration (AMD) 
with variants of apoE [1], followed by the family-based linkage studies that identified multiple loci for 
advanced AMD. Two of the major loci that were reported in several family-based linkage studies, 
1q31 and 10q26 were the subject of candidate gene testing of variants in both family-based and  
case-control cohorts and led to the discovery of the roles of complement factor H (CFH) [2–5] and the 
ARMS2/HTRA1 genes [6,7] in AMD risk. At approximately the same time, two genome-wide 
association studies (GWA) studies [8,9] also identified associations of variants in these two genes with 
AMD. Multiple candidate gene association studies were undertaken (for review see: [10]) particularly 
of the genes regulating the alternative complement pathway, confirming risk alleles in C2/BF, C3, and 
others [11]. Later, large-scale GWA studies with case-control cohorts confirmed these associations as 
well as with other genes in the complement pathway, lipid metabolism pathways and extracellular 
matrix biosynthesis and regulation. In addition, several genetic loci that were novel with respect to 
these pathways have also been found [10]. At present, 20 autosomal genetic loci have common 
variants with statistically significant associations with AMD. Mitochondrial genetic variants [12–16] 
as well as rare variants in several genes, notably CFH, CFI, C9 and C3 [17–21], have been implicated 
in AMD pathogenesis. 
Yet, with all these discoveries, we still cannot account for the complete heritability of AMD.  
There are individuals across the spectrum of AMD risk who will develop the condition despite 
relatively low genetic risk and others who will not progress to advanced disease, even with several 
high-risk variants. Further, our risk prediction models are inadequate for use in the preclinical AMD 
population. Some of this may be due to epigenetic phenomena that have not yet been considered,  
gene-gene interactions or the effects of other exogenous contributors such as smoking and diet as well 
as the human microbiome. Further genetic studies may refine our risk models, but it will remain a 
challenge to know how to interpret the impact of rare variants on genes associated with AMD, 
particularly when those variants do not affect protein structure. 
If one of our primary goals in AMD research is to delineate the pathobiology of the condition, then 
we are well on our way to achieving that goal, though it will take more than population-based genetic 
association studies to understanding the underlying biological interactions and pathways. It is 
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important to remember that complex genetic conditions are not simply heterogenous collections of 
disorders, nor do they follow the classic laws of causality that are attributed to Mendelian genetic 
disorders. They represent relatively subtle derangements of normal biological processes that over time 
lead to a dysregulated state associated with a disease process [10]. Some rare variants related to AMD 
may have sufficient penetrance to mimic a Mendelian genetic disorder [18–20], but most of the 
common variants appear to have a probabilistic impact on disease risk rather than being necessary  
and sufficient.  
If we are hoping to use the molecular genetics of AMD as part of personalized medicine with the 
intention of the early recognition of at-risk individuals to prevent or reduce the impact of disease, then 
we need to combine genetics with another set of tools to achieve the sensitivity and specificity to 
appropriately target the population for treatment. These tools are either to detect preclinical functional 
and/or structural derangements in the retina/RPE/choroid complex or to measure dynamic levels of 
molecules in the blood or eye (biomarkers) that are associated with AMD and which reflect both 
genetic and exogenous influences on pathways that contribute to AMD pathogenesis. There is obvious 
overlap of these two approaches since instruments that can measure levels of specific molecules in the 
eye and localize them are both defining structural changes (at a molecular level) in the retina and at the 
same time are employing the classical concept of measuring a biomarker with respect to measuring 
quantitative levels of a specific molecule. For structural and functional changes in the retina and 
biomarkers, we are striving for sensitivity without a specific requisite of specificity since it is 
unreasonable to expect any given pathway to only be reflected in AMD pathogenesis. For example 
serum C-reactive protein levels have been shown to be useful in risk models for heart disease but they 
are also altered in people with an array of autoimmune or infectious disorders [22,23]. Light or dark 
adaptation kinetics of the retina might be useful indicators of early AMD-related retinal dysfunction 
but they certainly are abnormal in many disease states that are unrelated to AMD.  
This paper examines and tests the concepts of how to use these tools in a complementary fashion 
with molecular genetics of AMD in order to achieve a clinically relevant predictive risk model. We 
must accept at the outset that such a model will be imperfect. It will be heavily influenced by the age 
of the individual and by other co-morbidities that share pathways that interact with AMD pathogenesis. 
The need for such a risk model is really predicated on the presumption that we will someday have a 
preventive therapy for AMD and that therapy will have costs and risks that make it appropriate to limit 
its use to those who are more likely to develop AMD. As long as our preventive options are avoidance 
of smoking, dietary modifications and supplements, then genetic testing has limited clinical relevance. 
However, given the efforts of the modern pharmaceutical industry to find an effective therapy for the 
large number of individuals at risk for AMD and the value of preserving sight in the elderly population 
(who are an increasing percentage of our population), then it is likely that therapies will emerge,  
first for those with clinically evident AMD and then extended to those with milder clinical or 
preclinical findings. 
In addition, the timing of when to institute a preventive therapy will be crucial since such treatment 
will inevitably alter normal physiologic pathways and thus not necessarily be desirable for an entire 
lifetime. At the same time, we want to start therapy sufficiently early in the disease to have optimal 
impact in preventing vision compromise. Thus it makes sense to have a process that can inform us as 
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to when to initiate therapy, as well as to monitor a biological response to that therapy (e.g., lowering of 
the risk for AMD incidence and/or progression) before disease is more clinically evident.  
Most clinicians have a strong intuitive sense of what constitutes a disease phenotype. Disease 
phenotypes are those observable features that are attributable to a specific condition [24]. They may 
represent the effects of a genetic mutation, genetic modifiers and/or exogenous factors. A single 
disease can have multiple phenotypic features and a specific phenotypic feature may be present in a 
number of conditions. For example, with AMD, there are a variety of clinically distinct forms of 
drusen, each of which can be considered a phenotypic feature [25–30]. At the same time a choroidal 
neovascular membrane (which is part of the definition of exudative AMD) is a phenotypic feature seen 
in a variety of ocular conditions. When multiple phenotypic features are present, it is possible that one 
or more may be obscured by another and thus phenotypic features of a disease may emerge or become 
obscured during the course of a disease. From a genetics standpoint, the appearance of the disease for 
that individual can change, but the phenotypic features that are observable at any time during the 
timeframe of the disease are what constitute the phenotype of that person’s condition. Phenotypic 
features not only define the clinical spectrum of the disease entity but they can play a critical role in 
predicting the rate of progression and likelihood of advanced disease. Examples of this for AMD 
would include large soft drusen and serous pigment epithelial detachments that are associated with an 
increased risk of developing advanced, exudative AMD.  
What is an endophenotype? The concept of endophenotype has several origins, but the term really 
gained acceptance in the psychiatric genetic literature [24,31], when clinicians, faced with the 
complexity of mental illness, were striving to find measurable traits that were associated with the 
disease, found in higher prevalence within families of individuals with that disease and which could 
serve as a surrogate when the clinical definition of the disease could not be met. Thus unlike a 
phenotype, an endophenotype can be measured or assessed even when the clinical state of disease is 
not present. To make the association with the disease in the first place, the endophenotype should be 
measurable in affected individuals (thus it can act as a disease phenotypic feature). It may not be 
present in all manifestations of the disease and throughout the lifetime of the condition, and it may 
have predictive value or not as to the future course or progression of the condition. However to be 
useful as an endophenotype (and not just as a disease phenotype), it must be measureable in clinically 
unaffected individuals and still be associated with disease. Note that a phenotypic feature that is 
associated with the disease doesn’t necessarily qualify as an endophenotype, unless it is observed in a 
higher frequency in family members of an affected individual in comparison with the frequency in the 
general population [31].  
In a sense, the most obvious endophenotype for AMD is the combination of the genetic risk variants 
themselves. As we have already discussed, a genetic risk model for AMD by itself is imperfect 
because there are a substantial number of individuals, particularly those with moderate risk profiles 
who will not eventually develop AMD. However as a group, one can look at cohorts defined by high 
and low genetic risks for AMD and have a reasonable expectation that a substantially higher 
percentage of individuals in the high-risk group will develop AMD as compared to the low-risk group. 
The genetic risk profile itself can serve as an endophenotype for AMD to then test whether or not other 
phenotypic features of AMD can also meet the definition of an endophenotype. If we have a functional 
test of the retina, such as dark-adapted thresholds or dark adaptation kinetics that we observe to be 
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abnormal in a significant number of AMD cases, it is reasonable to consider these abnormalities to be 
phenotypic features of AMD [32–39]. It doesn’t have to be universally observed and they may be 
useful for distinguishing subtypes of AMD. However to test whether or not these functional measures 
can serve as endophenotypes, we have to first show that they are abnormal in a higher percentage of 
the younger at-risk family members of affected individuals than would be observed in the general 
population. One can test this hypothesis directly by conducting a family-based study of adult children 
with one or more parents with AMD and using a population-based control group (such as the spouses 
of those adult children). Alternatively one can construct a case-control study design using the genetic 
risk profile of individuals as determined from the multiple common variants associated with AMD. 
This latter approach is much simpler since one doesn’t have to recruit within families and virtually 
every individual who is tested for the functional state can contribute to the analysis based on their 
AMD genetic risk profile. Another challenge in using the family-based approach is ensuring that one 
can effectively recruit a suitable control population since there may be a hidden genetic bias if one 
exclusively uses relatives (many of whom are presumably presymptomatic), but we have found that 
recruiting normal adults (ages 50–65) with no family history of AMD for functional testing is far more 
difficult than enlisting individuals who have a heightened awareness of AMD because of one or more 
affected parents. While both strategies can be used to test the suitability of a phenotypic feature to be 
an endophenotype for AMD [40], they are not identical. A recent paper by Aiyar et al. [41] showed a 
poor correlation of a personal family history with genomic testing for a complex disorder such as 
AMD. Their conclusion is that the discordance suggests that these two approaches for determining 
familial risk incorporate overlapping information and are partly complementary. They recommend the 
incorporation of both genomic information and a family history to improve risk assessment.  
Clinicians often consider potential AMD endophenotypes in three categories—structural, functional 
and molecular, but we should recognize that these distinctions are based more on acquisition 
technologies rather than on any conceptual distinctions. Most of the literature refers to biomarkers as 
in the measurement of small molecules in the blood (lipids, proteins, solutes), which reflect a systemic 
state. However biomarkers can also be localized, such as the measurements of retinal autofluorescence 
for A2E [42], intrinsic fluorescence [43], or macular carotenoids [44,45] with fundus imaging.  
Redox-based imaging based on differential fluorescence of NAD/NADP and NADH/NADHP in the 
cornea [46] or oxidized hemoglobin in the brain [47] are additional examples in which functional 
imaging and biomarker quantitation can be integrated. New noninvasive technologies may make it 
possible to determine levels of amyloid elements and specific metabolites in the in vivo retina/RPE. 
Functional testing of the retina reflects complex pathways and processing, but under certain conditions, 
as in a Vitamin A deficiency, can be a surrogate for retinoid availability and processing in the retina 
and be responsive to vitamin A intake or medications that block vitamin A transport [48].  
It is well known that deficits in rod-mediated retinal function occur as a natural consequence of 
normal aging [36,49–52] a process that may be accelerated in age-related macular degeneration 
(AMD) [34,38,39,49,53–56]. There are numerous psychophysical studies that have demonstrated 
decreases in rod-mediated sensitivity and prolonged dark-adaptation kinetics even in early  
AMD [33,34,36,38,39,54–59]. Thus, many have proposed scotopic thresholds as a potential 
endophenotype. Others have suggested that evaluating kinetic processes rather than threshold levels 
may be more sensitive indicators of early retinal dysfunction [38]. Thus, regional dark adaptometry, 
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which measures the kinetics of rod and cone photoreceptor adaptation are functional tests that may be 
potential AMD endophenotypes. 
As noted above serum biomarkers generally reflect a systemic state that may be indicative of an 
increased or decreased risk for developing disease. While it easier to gain access to the many 
metabolites and elements within the blood for large-scale assays, they pose a far greater challenge to 
relate these biomarkers to AMD than biomarker approaches that are focused on the tissues directly 
altered by AMD. Given the genes and variants implicated by AMD genetic association studies, one 
would consider serum biomarkers that reflect the dynamic states of lipid metabolism  
(e.g., apolipoprotein E), retinoid uptake and transport, carotenoid transport, inflammatory markers 
including C-reactive protein, circulating complement factors and regulatory proteins, and cytokines. 
However using these serum biomarkers is problematic in that they reflect complex interactions that 
include host genetic variants, diet, exogenous exposures, exercise, and the bacterial microbiome and 
other disease states. Depending on the prevalence of these mitigating factors, a biomarker may be 
informative for AMD risk in one cohort and not another. To effectively employ serum biomarkers in 
the general population, one needs a vast amount of data to establish how these molecules vary with 
age, gender and numerous co-morbidities and exposures so that one can determine if these modifiers 
contribute to the value of a biomarker for assessing AMD risk or if they confound their use. For 
example, there is evidence that the risks for heart disease and stroke are lowered by reducing serum 
cholesterol with statins and/or diet [22,60,61]. In this case, the fact that the biomarker can be modified 
by diet or medication does not detract from its value as a risk factor for these late stage cardiovascular 
diseases. In contrast, using CRP as a risk factor for heart disease is confounded when the individual 
has a systemic inflammatory disease and it is generally recommended that this biomarker not be used 
in this subset of the population [22]. 
As we consider the spectrum of potential endophenotypes for AMD including those that are potentially 
modifiable biomarkers, it is clear that testing these hypotheses is not the same as evaluating these indicators 
as AMD-related phenotypes. Looking for differences with these “markers” between AMD cases and 
controls may help to establish if they are associated with AMD (the first requirement for an 
endophenotype) but doesn’t evaluate the requirement than an endophenotype is detectable in individuals 
with an increased risk for developing AMD who have not yet demonstrated clinical disease.  
We recently shifted our longitudinal study of at-risk AMD family members and their spouses to 
specifically evaluate potential structural and functional alterations as potential endophenotypes for 
AMD. As suggested above, we incorporated the use of the genetic profile to determine a risk score in 
unaffected family members. We then tested the association between these risk profiles and  
dark-adapted rod- and cone-mediated threshold sensitivities and any subtle structural changes (before 
the appearance of drusen) that may be observed by optical coherence tomography. 
2. Experimental Section  
2.1. Subjects 
Ninety-eight subjects (mean age = 59.8 ± 4.3 years, range 51 to 69 years) participated in this 
prospective study. Subjects were recruited based on the presence of a family history of AMD in one or 
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both parents. All subjects underwent a complete ophthalmological exam by a retina specialist (MBG) 
and were segregated based on funduscopic appearance and OCT measures as normal (not AMD) or 
abnormal (AMD). We first performed a volume scan consisting of 61 full-width (30°) scan lines, each 
consisting of the average of 9–15 high resolution (HR) scans. These images were carefully examined 
to determine whether drusen, the hallmark of AMD, was present in either eye and was used primarily 
to classify the subjects as having a normal or AMD retina. Short-wavelength and near-infrared 
autofluorescence images were also examined to assess alterations that might be characteristic of AMD. 
Because these subjects were recruited based on a family history of AMD, but without visual symptoms 
and/or a clinical diagnosis of AMD, the majority of the participants had a normal fundus appearance 
(42 subjects).  
Because our focus in this study was on examining structural and functional biomarkers that might 
be predictive of the development of AMD, those with a diagnosis of AMD of any type were not 
studied further. Group characteristics are shown in Table 1. The study was carried out with approval of 
the UCLA and University of Pittsburgh Institutional Review Boards (IRB), informed consent was 
obtained from all subjects prior to participation, and the study was conducted in accordance with 
regulations of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  
Table 1. List of single nucleotide polymorphisms (SNPs) used to calculate the age-related 
macular degeneration (AMD) genetic risk score and the genotyping success rate. 
# Marker 
Genotyping 
Success Rate
Chromosome Location Gene 
1 rs10737680 0.979 1 196,710,325 CFH 
2 rs6795735 0.985 3 64,719,689 ADAMTS9-AS2 
3 rs13081855 0.9625 3 99,762,695 COL8A1 
4 rs4698775 0.9985 4 109,669,323 CFI 
5 rs3130783 0.958 6 30,806,580 C2-CFB-SKIV2L 
6 rs429608 0.997 6 31,962,685 SKIV2L 
7 rs943080 0.997 6 43,858,890 VEGFA 
8 rs3812111 1 6 116,122,572 COL10A1 
9 rs13278062 1 8 23,225,458 
TNFRSF10B-
LOC389641  
10 rs334353 0.9925 9 99,146,083 TGFBR1 
11 rs10490924 0.9895 10 122,454,932 ARMS2 
12 rs9542236 1 13 31,245,188 B3GALTL  
13 rs8017304 1 14 68,318,360 RAD51B 
14 rs920915 0.997 15 58,396,268 LIPC 
15 rs1864163 0.994 16 56,963,321 CETP 
16 rs4420638 0.964 19 44,919,689 APOC1/APOE 
17 rs8135665 0.994 22 38,080,269 SLC16A8  
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2.2. Genetic Analysis 
Our cohort of “at-risk” participants was screened for variants in genes commonly associated with 
AMD, including ARMS2 and HTRA1, two genes in strong linkage disequilibrium on chromosome 
10q26, as well as genes of the complement system. Genotyping of 743 individuals which included the 
subset of individuals in this phenotype-genotype study was done with an iPLEX panel of 88 SNPs that 
have been selected for known genes associated AMD and with the complement activation cascade, 
including CFH and CFH-related genes, CFI, C2/BF, and C3. The raw data was run through dbVor,  
a database system developed by Baron and Weeks for importing, editing and exporting genotype data, 
to generate the data in Mega2 format [62]. dbVor’s statistics excluded 3 markers with no measurable 
genotypes. Mega2 was used to convert the data to PLINK [63]. SNP’s with genotyping success  
rates <0.9 were removed (18 SNPs) and individuals with genotyping success rates of <0.9 were also 
excluded. The genetic loci for the 17 of the 19 risk SNPs that were included in the computation of the 
genetic risk score are described elsewhere [64]. The two markers, rs2230199 and rs5749482, were 
removed because of excessive genotyping failure rates, 28.94% and 10.36%, respectively. All of the 
markers used in the AMD genetic risk score calculation showed no evidence of violation of the Hardy 
Weinberg Equilibrium. 
 
(1)
 (2)
The 17 loci can distinguish cases and controls relatively well (area under the receiver operator curve 
(AUC) = 0.74) [64]. The risk score computation used the formula from the Nature Genetics paper  
(see below) [63]. In their approach, they normalized the betas by dividing them by the sum of the 
betas. The score is then the sum over all the observed genotypes of the normalized beta multiplied by 
the number of risk alleles. This score ranges from zero to two. 
Individuals, whose DNA yielded low quality genotyping scores or more than two missing 
genotypes, were excluded from these analyses. The cohort of participants that were classified as 
normal based on a normal OCT and fundus exam, were further sub-divided into two groups based on 
the presence or absence of AMD risk alleles. 
2.3. Microperimetry 
Fundus-guided sensitivity measures were obtained with a Nidek MP-1S microperimetry system 
(Nidek Technologies, Italy). Sensitivity measures were obtained at discreet locations (0°, 2°, 5°, 10°, 
14°) spanning the horizontal and vertical meridian of both eyes. Stimulus size was equivalent to 
Goldmann V (2.0°) with flash duration of 200 msec. A 4-2 thresholding strategy was employed in 
derivation of sensitivity measures. Participants were dilated (0.5% tropicamide hydrochloride and 1% 
phenylephrine hydrochloride) and dark-adapted for at least 30 minutes in a light-tight room prior to 
data collection. An array of four small crosses arranged in a diamond was used to align and maintain 
fixation, each cross 3° from the anatomical fovea. After instruction and training, sensitivity was first 
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measured using a long-wavelength “red” stimulus (Edmund Optics, red dichroic filter, NT30-634). The 
red series was presented first to establish locus of fixation and reliability estimates. A 1.0 neutral 
density filter could be inserted into the optical pathway to extend the range of flash intensities to 
approximately 30 db. Immediately after, sensitivity to a short-wavelength “blue” stimulus (Edmund 
Optics, blue dichroic filter, NT30-635) was measured in exactly the same locations as those for the red 
flashes. Up to a 3.0 log unit neutral density filter could be inserted into the optical pathway to extend 
the range of flash intensities to approximately 50 db. In instances where the threshold spanned the 
boundary between two ND filters, the field was first measured with the denser filter and then replicated 
with the next less dense filter. Only in case where the threshold was indeterminate at one filter density 
was the lower density filter used. All starting eyes were counter-balanced across all participants, 
except in cases of maculopathy where the better eye was tested first. 
2.4. Optical Coherence Tomography 
Retinal structure for all participants was measured with spectral-domain optical coherence 
tomography (sdOCT) (Heidelberg Engineering, Germany). We first performed a volume scan 
consisting of 61 full-width (30°) scan lines, each consisting of the average of 9–15 high resolution 
(HR) scans. These images were carefully examined to determine whether drusen was present in either 
eye. We then recorded a high-resolution vertical and horizontal scan centered on the anatomical fovea. 
These images were imported into custom software (Igor Pro; WaveMetrics, Inc., Portland, OR, USA) 
to segment the different retinal layers as previously described [65–68]. For the purposes of this study 
we report thickness measures for Outer Limiting Membrane (OLM)—Bruch’s membrane, Outer 
Nuclear Layer (ONL), and full retinal thickness. 
In addition to the thickness measures, we also derived light reflectance profiles (LRPs) across the 
retina to measure the relative intensities of the bands seen on the OCT. A high resolution, 30° vertical 
scan centered on the fovea was used for analysis. Images were imported from native HEYEX software 
into NIH’s ImageJ (http://imagej.nih.gov/ij, v1.46r, 64-bit) and cropped to include only the OCT scan. 
After the image was calibrated to match the original scan’s spatial resolution, a 1 mm wide section of 
the retina was sampled from Bruch’s membrane (BM) to the inner limiting membrane (ILM).  
Sections centered 1 mm superior and inferior of the fovea were taken. Reflectance profiles were 
created for each section; values were then divided by the mean gray-scale intensity of the section, thus 
normalizing plots across patients. To account for varying retinal thicknesses, total retinal thickness was 
normalized to 1.0 for each eye. 
3. Results 
3.1. Characteristics of the Study Population 
Ninety-eight subjects were recruited for this study. All participants underwent a complete 
ophthalmological exam by a retina specialist (MBG) and were segregated based on funduscopic 
appearance and OCT measures as normal (not AMD) or abnormal (early or intermediate AMD). 
Fundus grading and AMD classification was done independently by two graders using the Beckman 
AMD Classification System. Eight of the 98 subjects were found to have significant epiretinal 
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membranes (ERM) in one or both eyes. These eyes were excluded from further study.  
Of the 98 subjects, 63 were found to have no clinical signs of AMD, 18 subjects were found to have 
early AMD (medium-sized drusen (diameter >63μ and ≤125μ) but without pigmentary abnormalities) 
and 13 subjects were found to have intermediate AMD (large drusen (diameter >125μ) or with 
pigmentary abnormalities associated with at least medium-sized drusen). No participants with late 
AMD (lesions associated with neovascular AMD or geographic atrophy) were identified in this study. 
Two subjects with funduscopic changes that were not consistent with AMD were excluded. 
3.2. Genetic Risk Scores are Associated with Fundus Appearance 
Genetic risk profiles for AMD based on 17 key SNPs as identified by the International AMD 
genetic consortium were determined for each participant. Individuals, whose DNA yielded low quality 
genotyping scores or more than 2 missing genotypes, were excluded from these analyses. Genetic risk 
scores were obtained for 69 participants and ranged from 0.61 to 1.62. As shown in Table 2, there was 
a clear association between AMD risk score and AMD categories based on retinal structural changes 
(no t-test comparing the risk scores among the three AMD categories had p-values >0.018).  
Table 2. Fundus grading and AMD classification using the Beckman AMD Classification 
System for the 69 individuals with AMD genetic risk scores. Genetic risk profiles for 
AMD were based on 17 key SNPs as identified by the International AMD  
genetic consortium. 
Fundus Grading based on OCT Imaging N  Mean Risk Score (±1 SD) 
Normal (no drusen)  43 1.07 (0.20) 
Early AMD (few small drusen)  12 1.24 (0.12) 
Intermediate AMD (multiple large drusen)  14 1.41 (0.19) 
3.3. The AMD Risk Score and Age Correlate with Clinical Findings 
Figure 1 displays the associations of age and AMD risk scores with respect to OCT-based evidence 
of early AMD (any small drusen), intermediate AMD (one or more large drusen), or no fundus lesions. 
Although considerable variability is apparent, individuals with intermediate AMD are both older and 
tend to have higher risk scores than those with early AMD or no lesions. Only a single person (age 57) 
with an AMD risk score greater than 1.4 had a completely normal fundus. Though more data are 
essential, the age distribution between 50 and 66 appears to be an appropriate range for endophenotype 
analyses and for defining progressive retinal anatomic changes. 
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Figure 1. The association between age and AMD genetic risk score (n = 69). Each data 
point represents a separate individual and is color-coded for AMD classification. The 
horizontal dashed lines indicate the mean risk scores for normal (no drusen), early AMD 
and intermediate AMD. 
  
3.4. Individuals with High-Risk Genetic Profiles Do Not Necessarily Exhibit Reductions in Scotopic 
and Photopic Sensitivity 
The majority of individuals with genetic risk but with normal fundus appearance and no drusen 
demonstrated normal scotopic and photopic threshold sensitivity (see Figure 2). However, we 
identified three individuals, subjects S38, S52, and S75, whose scotopic sensitivities were clearly 
reduced from normal but with cone threshold sensitivities that were within normal limits, although 
toward the lower limits of normal. This finding is consistent with numerous studies of dark-adapted 
visual function in early AMD showing greater rod- than cone-dysfunction (e.g., [54]). As a measure of 
the relative loss of rod function, a ratio of rod to cone sensitivity was formed. For the cohort with 
normal rod and cone sensitivity, the ratio was 1.77 (±0.1), whereas for the three outliers, the average 
ratio was 1.5 (±0.18). The average genetic risk score was comparable between the two groups at  
1.07 (±0.24) and 1.12 (±0.12), for the normal and reduced sensitivity cohorts, respectively. However 
there is considerable variability in both rod- and cone-mediated thresholds among the participants that 
might be relevant to the phenotypic characterization of subtypes of AMD. 
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Figure 2. Final thresholds measured psychophysically with dark-adapted microperimetry. 
Right (OD) and left (OS) eyes are shown separately as circles and squares, respectively. 
Normal ranges (±2.0 SD) are shown as dashed lines for rod-mediated function (blue lines) 
and for cone-mediated function (red lines). 
 
3.5. Reduced Rod-Mediated Threshold Sensitivity in Patients with Normal Fundus Is Not Clearly 
Accompanied by Retinal Structural Changes in the Absence of Drusen 
We then asked whether the loss of sensitivity observed psychophysically was accompanied by 
retinal structural change as measured by OCT. For this purpose, we studied the three patients with 
significantly reduced rod sensitivity (S38, S52 and S75) and compared retinal layer thickness measures 
with three patients with normal to above average sensitivity (S14, S34 and S02) (see Figure 2).  
The average age of patients in the two groups was 60.3 and 58.3 years, respectively. First, we 
segmented vertical sections of the high-resolution OCT images to obtain thickness measures for the 
OS+ (defined as the thickness from the ISe to Bruch’s membrane), the outer nuclear layer (ONL), and 
total retinal thickness (TR). The vertical section bisected the anatomical fovea. Average thickness 
measures for the normal sensitivity group were 55.3 (+4.0), 63.8 (+2.43), and 287.7 (+7.6) μm for 
OS+, ONL, and TR, respectively. The corresponding measures for the three patients with low 
sensitivity were 58.2 (+2.5), 68.6 (+4.8), and 298.8 (+10.7) μm. An example of the imaging 
segmentation and scotopic/photopic threshold regional measurements are shown in Figure 3. 
Surprisingly, all three measures demonstrate a modest thickening of the measured layers in the low 
sensitivity group compared to the normal sensitivity, although there is considerable overlap in the 
distributions of measures. Whether these modest changes in retinal layer thicknesses represent early 
retinal changes that predict the development of early AMD is not known. However, abnormal 
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thickening and thinning of the photoreceptor layer has been previously reported in intermediate  
AMD [69]. 
Figure 3. Structural and functional measurements for subject S38 (see Figure 2) with 
normal appearing retina and no drusen. A: Rod- (blue) and cone- (red) mediated threshold 
sensitivities at discreet locations along the vertical axis bisecting the anatomical fovea. 
Normal sensitivity limits are defined by the shaded areas for rods (upper shaded area) and 
for cones (lower shaded region); B: Retinal thickness (TR) measurements along the same 
vertical axis for the TR (upper panel), outer nuclear layer (ONL) (middle panel) and the 
OS+ (lower panel). In each panel, the normal limits are defined by the shaded regions.  
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3.6. The Relative Brightness of the Bands Seen on OCT in Those Individuals with Reduced Scotopic 
Sensitivity Is Not Reduced? 
A prominent feature in retinal disease is the disruption of a reflectant band now referred to ellipsoid 
band (ISe) of the inner segment [70]. This highly visible band has been shown to be absent or 
disrupted in macular holes [71,72] acute zonal occult outer retinopathy (AZOOR) [73], epiretinal 
membranes [74], age-related macular degeneration [75–78], and retinitis pigmentosa [66]. Moreover, a 
recent study has suggested that both rods and cones contribute to the integrity of this band, becoming 
less intense in disease affecting primarily cones, and entirely absent when rod- and cone 
photoreceptors are absent [66]. These findings may provide a novel marker of disease severity in  
pre-symptomatic AMD. To investigate this possibility, we measured the light reflectance profiles 
(LRPs) in the midperipheral retina (see Figure 4) to measure the relative intensities of the bands seen 
on the OCT in those patients (S38, S52 and S75) with abnormal scotopic sensitivity, but with 
otherwise normal-appearing retina. As can be seen in Figure 4, there were no significant differences in 
the LRP in these patients compared to those with normal sensitivity (show as black lines are the upper 
and lower limits for normal). 
Figure 4. Light reflectance profiles (LRP) across retinal layers as imaged by OCT. A  
1 mm wide section of the retina (shown as the rectangle in the OCT image below) was 
sampled from Bruch’s membrane (BM) to the inner limiting membrane (ILM). Sections 
were centered 1mm superior and inferior of the fovea. In the bottom panels, the normal range 
of LRP are defined by the solid black lines. The LRPs for the three patients (S38, S52 and S75) 
with significantly reduced retinal sensitivity and normal appearing retina are shown as red 
lines. Note that the LRP for these representative subjects are well within normal limits.  
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4. Conclusions  
In this minireview and research communication, we have discussed the concepts of phenotypes, 
endophenotypes and biomarkers in the context of age-related macular degeneration. We have 
attempted to show that the genetic risk profiles based on common SNPs can serve as a valid 
endophenotype for AMD, particularly in younger, individuals with minimal or no clinical findings of 
AMD. The high correlations of early and intermediate AMD (as detected by spectral domain OCT) 
with the AMD genetic risk profile lends strong support to this assertion. These genetic risk  
profiles allow us to test hypotheses that specific biochemical changes, imaging parameters and/or 
psychophysical measurements can be tested for abnormalities that precede the onset of clinical 
findings of AMD. Others [79] have also begun to employ this strategy. While a number of 
abnormalities of retinal structure and function have been implicated as AMD phenotypes, we have 
shown that some of these parameters, such as scotopic thresholds, do not fulfill the criteria as 
endophenotypes for AMD and do not contribute to our ability to refine the risk models that we 
currently have available. However this is not intended to imply that other parameters such as dark 
adaptation kinetics and rod- and cone-mediated temporal acuity may not prove to be validated in the 
future. There is considerable value to be gained from continuing studies of these phenotypes to better 
define subtypes of AMD and the prognosis of those who have clinical evidence of AMD.  
The genetic risk model for AMD may be slightly enhanced by future discoveries of both common 
and rare variants for AMD, but it is unlikely that it will achieve sufficient sensitivity and specificity to 
be used in isolation in a presymptomatic, at-risk pool of individuals. Family history also can play a 
useful role in assessing a patient’s risk of AMD but it is not sufficient by itself. In our cohort, that was 
drawn from individuals with a positive family history for AMD and also genotyped for a number of 
AMD-risk related SNPs, we observed only a single participant with an AMD risk score greater than 
1.4 who had a completely normal fundus. However this discrimination ability will be less clear as 
more and younger at-risk individuals undergo high-resolution retinal imaging.  
Commercially available tests such as ArcticDX™ and Retnagene™ have already incorporated 
clinical findings, age and smoking exposure to dramatically improve the predictive ability of their 
models. However these tests are not appropriate for individuals who have no evidence of AMD and 
who might wish to know if they should take steps to lower their risk of developing AMD. Genetic 
testing for these individuals is not appropriate since none of the risk reduction approaches for AMD 
(nutrient supplements, avoidance of smoking, healthy diets and exercise) are associated with sufficient 
additional costs or risks to employ genetics-based coercive and/or selective strategies.  
The potential value of serum and/or retinal biomarkers to monitor pre-disease risk and response to 
therapy is undisputed but remains elusive. It will take considerable effort to validate these markers, 
particularly those that are subject to fluctuations in association with other acute and chronic conditions. 
Prospective, long-term studies that are focused on high-risk cohorts and lasting 5 to 10 years  
(similar to the ARED Study) will be required to test and confirm the utility of these markers. Such 
studies are unlikely to be funded by NIH at this time but it may be possible to compile sufficient 
preliminary data with smaller, short-term retrospective studies to warrant a clinical trial. Any current 
or planned clinical trials for AMD therapy which are evaluating disease progression should seriously 
consider acquiring serum and/or plasma samples as well as DNA for these investigations so that one 
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can use the careful phenotypic analyses and documentation of incident disease and progression for 
association testing. 
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